Business
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Aug.
About this update from Geovax Labs, Inc.
[{"type":"text","content":" Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the Emerging Growth Conference on September 6, 2023. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Chairman and CEO, David Dodd, in real time. Presentation Details:Presenter: David Dodd, Chairman & CEODate/Time: 1:45pm ET, September 6, 2023Registration Link: https://goto.webcasts.com/starthere.jsp?ei=1603285&tp_key=ab3efc5870&sti=govx Please register here to ensure you are able to attend the conference and receive any updates that are released. Following his presentation, Mr. Dodd will open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Dodd will do his best to get through as many of them as possible. About the Emerging Growth Conference The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community. The conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions are conducted through video webcasts and take place in the Eastern time zone. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 ...